IC19 CAR-T cells
/ Beijing Imunopharm
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 20, 2025
Clinical Study Evaluating the Safety and Efficacy of IC19 CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
(clinicaltrials.gov)
- P1 | N=6 | Not yet recruiting | Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.
New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
1 to 1
Of
1
Go to page
1